North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury: A Consortium of Military, Veterans Administration, and Civilian Hospitals
Addendum to final rept. 1 Jan 2010-31 Dec 2010
CHRISTOPHER REEVE FOUNDATION SHORT HILLS NJ
Pagination or Media Count:
Four hundred forty-one acutely injured patients have been enrolled in the NACTN data registry as of 162011 enrollment continues at all clinical centers. 24 acutely injured patients have been enrolled in the Riluzole Phase I safety study to-date, no adverse reactions to the drug have been reported. NACTN has reorganized itself and now operates under a formally adopted Governance Manual and Policies Procedures and works through established committees oversight for all NACTN operations is vested in its Executive Committee. Under the aegis of its Neurological Outcomes Committee NOA, three contracts have been issued to develop and finalize three new outcome instruments. A book chapter on NACTN is in press the network has submitted its first manuscript for publication two manuscripts are in preparation by Dr. Diana Chow and the Publications Committee is exploring a NACTN focus issue with J Neurosurgery. NACTN s Treatment Strategy Selection Committee is recommending consideration of a Phase III randomized, controlled trial of Riluzole. Several NACTN investigators met with investigators from the European EM-SCI network and agreed to begin the process of data sharing, which will also include data from the STASCIS trial and from the Reeve Foundation s NeuroRecovery Network. Dr.Grossman and Colonel Randall McCafferty have discussed San Antonio Military Medical Center SAMMC joining NACTN, which they anticipate can be finalized during Q1 2011.
- Anatomy and Physiology
- Medicine and Medical Research